Haldol Depot Stungulyf, lausn 100 mg/ml Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

haldol depot stungulyf, lausn 100 mg/ml

essential pharma limited - haloperidolum dekanóat - stungulyf, lausn - 100 mg/ml

Haldol Tafla 1 mg Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

haldol tafla 1 mg

essential pharma limited - haloperidolum inn - tafla - 1 mg

Haldol Stungulyf, lausn 5 mg/ml Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

haldol stungulyf, lausn 5 mg/ml

essential pharma limited - haloperidolum inn - stungulyf, lausn - 5 mg/ml

Polivy Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

polivy

roche registration gmbh - polatuzumab vedotin - eitlaæxli, b-klefi - Æxlishemjandi lyf - polivy ásamt bendamustine og rítúxímab er ætlað fyrir meðferð fullorðinn sjúklinga með fallið/svarar dreifð stór b-eitlaæxli (dlbcl) sem eru ekki mönnum fyrir skurðaðgerðir stafa klefi grætt. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Zeposia Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod stutt og long-term - multiple sclerosis, relapsing-remitting; colitis, ulcerative - Ónæmisbælandi lyf - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Lenzetto Úði til notkunar um húð 1,53 mg/úðaskammt Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

lenzetto úði til notkunar um húð 1,53 mg/úðaskammt

gedeon richter plc.* - estradiolum inn - Úði til notkunar um húð - 1,53 mg/úðaskammt